Concerning “The use of recombinant luteinizing hormone in patients undergoing assisted reproductive techniques with advanced reproductive age: a systematic review and meta-analysis”

30 04 2012

To the Editor:

With great interest we read the article by Hill et al. (1) on the use of recombinant luteinizing hormone (r-LH) in patients of 35 years and older undergoing assisted reproductive techniques. The use of r-LH supplementation during ovarian stimulation as part of assisted reproduction treatment is controversial and literature shows conflicting results in women of 35 years and older. The available evidence does not support the hypothesis that the addition of r-LH increases the pregnancy rate in unselected patients treated in an IVF/ICSI protocol with recombinant FSH and a GnRH agonist or antagonist. But there might be a potential benefit of the use of r-LH supplementation during ovarian stimulation in women with a poor response and women of advanced age (2). An update and systematic review and meta-analysis focused on women of 35 years and older is therefore timely and of great value with regard to possibilities to individualize treatments to improve outcomes. Read the rest of this entry »